{"database": "lobbying", "table": "lobbying_activities", "rows": [[2871172, "9af693e1-c562-4b1d-a880-ad0d3fa9f356", "Q3", "ELI LILLY AND COMPANY", 13392, "ELI LILLY AND COMPANY", 2022, "third_quarter", "CSP", "Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; \"Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)", "Commerce, Dept of (DOC),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)", null, 1210000, 0, 0, "2022-10-18T13:01:58-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2871172"], "units": {}, "query_ms": 42.34671301674098, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}